ETC-159 plus pembrolizumab for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two drugs—ETC-159 (a pill that targets a specific growth pathway) and pembrolizumab (an immunotherapy)—for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ovarian cancer that has stopped responding to platinum-based chemotherapy or progressed within 6 months of your last treatment.
- Your tumor is 'MSS' or 'pMMR' (a type of genetic marker).
- You are able to swallow pills and have a caregiver who can help if needed.
- You do not have active brain metastases, osteoporosis, or certain other bone conditions.
- You have not had certain other cancers or autoimmune diseases in the past few years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, EZH2 inhibitor and PARP inhibitor, for people with advanced or recurrent epithelial ovarian cancer that does not have BRCA1/2 gene mutations. The goal is to see if this combination can shrink tumors or slow the disease.
This Phase 2 trial tests whether adding pembrolizumab (an immune medicine) to standard chemotherapy can improve outcomes for people with small cell cancer of the ovary that has not been treated before. It may help your immune system recognize and attack the cancer while you receive chemotherapy.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
Hear when a new With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.